Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Neutropenia (Feb 2019)

Posted by Matt Breese on Feb 1, 2019

Find me on:

According to our recent payer coverage analysis for neutropenia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for neutropenia treatments shows that about 40% of the covered lives under the pharmacy benefit in commercial and health exchange formularies have utilization management restrictions. 

MMIT-Reality Check-neutropenia_1Q2019Data snapshot as of Q1 2019

Trends: The surge of pipeline biosimilars will mean increased competition. Granix and Zarxio utilization is on the rise, which is taking market share from Neulasta and Neupogen . Via AIS Health.

To read the full Reality Check on Neutropenia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing